Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric M. Dube Sells 18,924 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric M. Dube sold 18,924 shares of the firm’s stock in a transaction on Monday, May 5th. The shares were sold at an average price of $21.05, for a total value of $398,350.20. Following the completion of the sale, the chief executive officer now owns 419,173 shares in the company, valued at approximately $8,823,591.65. This represents a 4.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Travere Therapeutics Trading Up 1.0 %

Shares of TVTX opened at $20.44 on Friday. Travere Therapeutics, Inc. has a 1-year low of $6.01 and a 1-year high of $25.29. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The firm has a 50 day simple moving average of $18.06 and a 200-day simple moving average of $18.80. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of -4.98 and a beta of 0.88.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.08. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The business had revenue of $81.73 million for the quarter, compared to analyst estimates of $77.44 million. During the same quarter last year, the company earned ($1.76) earnings per share. The business’s revenue for the quarter was up 83.3% compared to the same quarter last year. Equities analysts forecast that Travere Therapeutics, Inc. will post -1.4 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on TVTX. Guggenheim restated a “buy” rating and issued a $47.00 price objective on shares of Travere Therapeutics in a research note on Monday, April 14th. Wedbush reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Travere Therapeutics in a research report on Friday, May 2nd. HC Wainwright boosted their target price on Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, January 15th. Stifel Nicolaus upped their price objective on shares of Travere Therapeutics from $22.00 to $23.00 and gave the stock a “hold” rating in a research report on Friday, May 2nd. Finally, Evercore ISI lifted their target price on shares of Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, Travere Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.79.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Driehaus Capital Management LLC grew its holdings in Travere Therapeutics by 608.1% in the 4th quarter. Driehaus Capital Management LLC now owns 2,217,975 shares of the company’s stock valued at $38,637,000 after buying an additional 1,904,733 shares during the period. BNP Paribas Financial Markets acquired a new position in Travere Therapeutics during the fourth quarter worth approximately $21,075,000. RA Capital Management L.P. purchased a new position in Travere Therapeutics during the fourth quarter worth approximately $20,033,000. Jennison Associates LLC acquired a new position in shares of Travere Therapeutics in the 4th quarter valued at $14,222,000. Finally, Jacobs Levy Equity Management Inc. grew its position in Travere Therapeutics by 36.7% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 2,174,213 shares of the company’s stock valued at $37,875,000 after acquiring an additional 583,836 shares during the period.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.